Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15

Innoviva, Inc.

2025-Q2 EPS reported $0.24 revenue$188,915,000

Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).
ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.
Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.
Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.